Top Tweets for #ASHKudo

9 months ago

#ASH25 #leusm #ALL #ASHKudo Phase III GIMEMA ALL2820: chemo-free targeted/immunotherapy beats TKI/chemo •Higher CHR + MRD responses, fewer deaths, better EFS/OS •More MRD negativity + fewer relapses vs prior trial •Crossover helps rescue MRD+ patients •Biology-driven transplant strategy effective •Chemo-free approach emerging as new standard for adult Ph+ ALL

TalhaBadarMD's tweet photo. #ASH25 #leusm #ALL #ASHKudo

Phase III GIMEMA ALL2820: chemo-free targeted/immunotherapy beats TKI/chemo
•Higher CHR + MRD responses, fewer deaths, better EFS/OS
•More MRD negativity + fewer relapses vs prior trial
•Crossover helps rescue MRD+ patients
•Biology-driven transplant strategy effective
•Chemo-free approach emerging as new standard for adult Ph+ ALL

Talha Badar @TalhaBadarMD

9 months ago

#ASH25 👇Key abstracts to watch in acute lymphoblastic leukemia #ALL #leusm 🧵 Overall Takeaways — ASH 2025 ALL Landscape Rapid movement toward chemo-free or chemo-lite regimens, especially in Ph+ ALL. TKI + immunotherapy (blina / InO) emerging as new standard-contenders. CAR-T earlier in therapy (CR1 consolidation & frontline). Expanding roles for bispecifics & venetoclax-based combinations in R/R ALL. MRD (especially NGS-MRD) central to future risk-adapted strategies.

TalhaBadarMD's tweet photo. #ASH25 👇Key abstracts to watch in acute lymphoblastic leukemia #ALL #leusm 🧵

Overall Takeaways — ASH 2025 ALL Landscape

Rapid movement toward chemo-free or chemo-lite regimens, especially in Ph+ ALL.

TKI + immunotherapy (blina / InO) emerging as new standard-contenders.

CAR-T earlier in therapy (CR1 consolidation & frontline).

Expanding roles for bispecifics & venetoclax-based combinations in R/R ALL.

MRD (especially NGS-MRD) central to future risk-adapted strategies.

14K

Top Tweets for #ASHKudo

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users